TScan Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of TCRX for the last quarter is 7.21 M USD, and it's 85.52% higher compared to the previous quarter. The net income of Q4 23 is -19.61 M USD.